Pfizer CEO announces Omicron vaccine to be ready by March

January 12, 2022 9:36 AM

The vaccine makers have been developing a new vaccine targeting the latest COVID strain.

Pfizer CEO Albert Bourla.

The Chief Executive of Pfizer Inc., Albert Bourla announced on Monday that a specific vaccine targeting the Omicron variant of the coronavirus will be the most likely outcome of efforts being made to tackle the swelling numbers of infections being caused by the latest strain.

Recommended articles

The announcement was made while Bourla was speaking at the J.P. Morgan Healthcare Conference whilst he commented on the partnership his organization has with BioNTech SE, merging efforts that should yield a vaccine targeting the Omicron variant.

With the dwindling fortunes of the previously issued vaccines against the Omicron variant, he said of the initial two shots adequacy at dealing with the new strain, “The two doses, they’re not enough for omicron,”. He then continued to say that “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”

Although the booster shots have been claimed to be 75% effective against symptomatic infections and 88% effective against hospitalizations, he said that the company will be ready with vaccines specifically targeting the Omicron variant by March whilst being sceptical about them still being needed by that time.

Seye Omidiora Seye Omidiora is a passionate football writer and pundit whose deep appreciation for the beautiful game exceeds the usual. He is currently a columnist for Goal Africa and has previously written for Vital Football UK, IBCity Info and Opera News.

Enhance Your Pulse News Experience!

Get rewards worth up to $20 when selected to participate in our exclusive focus group. Your input will help us to make informed decisions that align with your needs and preferences.

I've got feedback!